Electronics
Computer Hardware
Cancer Prevention

Anixa Biosciences

$4.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-3.20%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ANIX and other stocks, options, ETFs, and crypto commission-free!

About

Anixa Biosciences, Inc. Common Stock, also called Anixa Biosciences, is harnessing the body's immune system in the fight against cancer. Read More Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Employees
8
Headquarters
San Jose, California
Founded
1982
Market Cap
91.32M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
125.99K
High Today
$4.84
Low Today
$4.52
Open Price
$4.72
Volume
27.82K
52 Week High
$6.86
52 Week Low
$2.96

Collections

Electronics
Computer Hardware
Cancer Prevention
Therapy
Biotechnology
Health
2015 IPO
US

News

PR Newswire14h

U.S. Department of Veterans Affairs and McGuire Research Institute Join Anixa Biosciences Cchek™ Prostate Cancer Study

SAN JOSE, Calif., March 25, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the Hunter Holmes McGuire VA Medical Center (VAMC) located in Richmond, VA has joined its ongoing prostate cancer Cchek™ study. Study enrollment will be led by Dr. Michael G. Chang, Service Chief, within the Radiation Oncology Department. "We are pleased to be working with Dr. Chang and the VAMC to further develop ou...

13
PR NewswireMar 14

Anixa Biosciences Announces Notice of Allowance for Additional Cancer Detection Technology Patent

SAN JOSE, Calif., March 14, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for an additional cancer detection technology patent. This patent provides broader coverage for the use of Anixa's technology in a wider range of applications and protects critical new improvements developed for Anixa's cancer det...

56
Simply Wall StMar 6

What Should Investors Know About Anixa Biosciences, Inc.’s (NASDAQ:ANIX) Earnings Outlook?

In October 2018, Anixa Biosciences, Inc. (NASDAQ:ANIX) announced its most recent earnings update, which signalled that losses became smaller relative to the prior year’s level – great news for investors Below, I’ve laid out key growth figures on how market analysts predict Anixa Biosciences’s earnings growth trajectory over the next couple of years and whether the future looks brighter. Note that I will be looking at net income excluding extraordinary items to get a better understanding of the underlying dr...

12
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.